GSK delays Japanese hair-loss treatment launch on Catalent plant problems

Suspected product tampering has put production at a French Catalent ($CTLT) plant on hold--and GlaxoSmithKline ($GSK) is paying the price. The British pharma giant has delayed the launch of hair-loss drug Zagallo in Japan while it searches for another manufacturing site. More from FiercePharma

Suggested Articles

Moving into the Final Four of the #FierceMadness drug name tournament, contenders from both Big Pharma and smaller companies remain evenly in play.

Eli Lilly bought full-page ads in more than a dozen newspapers in the U.S. to let people with diabetes who use Lilly drugs to know help is available.

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.